Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-091793
Filing Date
2024-08-06
Accepted
2024-08-06 16:09:34
Documents
68
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rani-20240630.htm   iXBRL 10-Q 1696077
2 EX-10.1 rani-ex10_1.htm EX-10.1 604881
3 EX-10.2 rani-ex10_2.htm EX-10.2 917
4 PDF COURTESY COPY rani-ex10_2.pdf EX-10.2 97423
5 EX-31.1 rani-ex31_1.htm EX-31.1 16877
6 EX-31.2 rani-ex31_2.htm EX-31.2 16914
7 EX-32.1 rani-ex32_1.htm EX-32.1 10154
  Complete submission text file 0000950170-24-091793.txt   8618448

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rani-20240630.xsd EX-101.SCH 1532831
70 EXTRACTED XBRL INSTANCE DOCUMENT rani-20240630_htm.xml XML 1237000
Mailing Address 2051 RINGWOOD AVENUE SAN JOSE CA 95131
Business Address 2051 RINGWOOD AVENUE SAN JOSE CA 95131 (408) 457-3700
Rani Therapeutics Holdings, Inc. (Filer) CIK: 0001856725 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40672 | Film No.: 241179281
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)